• 

Fri. 09/28
Poster session 2 (P30-P39) / 1.15 - 2.00 pm
Poster Session 2
Chairman 1: R. Banares, Madrid, Spain / Chairman 2: A. Kribben, Essen, Germany

01.15 - 02.00 pm	P30	Neogenesis of liver struactural units after cotransplantation of liver and bone marrow cells as a basis for prolonged recovery of damaged liver M. Shagidulin, Moscow, Russia
	P31	Impact of Albumin Dialysis on  Albumin Binding Function    - an in vivo study M. Kretschmann, Rostock, Germany
	P32	Efficient differentiation of human induced pluripotent stem cells to definitive endoderm on functionalized nanofibers M. Kazemi-Ashtiani, Tehran, Iran
	P33	Prospective validation of cross organ serum protein biomarkers – Initial results with CXCL9 and CD44 for diagnosis of acute liver rejection K.A. Prabowo, Berlin, Germany
	P34	Association of OASL gene with chronic HCV therapy response to pegylated interferon-α and ribavirin S. Kiprijanovska, Skopje, Macedonia
	P35	Characterization of liver cell culture in micro-fluidic biochips by a real time imaging analysis M. Naudot, Compiégne, France
	P36	Experience of application of Prometeus liver support therapy on patients with hepatorenal syndrome Y. Santotski, Minsk, Belarus
	P37	Comparison of Extracorporeal Liver Assist System (ELAD®) vs. Standard Care in Treating Chinese Patients with Acute-on-Chronic Liver Failure Z. Duan, Beijing, China
	P38	Hepatocyte toxicity of industrial stabilizers in commercial human serum albumin M. Stiffel, Rostock, Germany
	P39	Impact of Albumin Dialysis on Albumin Binding Function  - an in vitro study L. Borufka, Rostock, Germany